Pharmaceutical Research 2003: Vol 20 Index

13 Pages·2003·3.3 MB·English

Pharmaceutical Research
\
Ac
Act
Ad
Ad
Ada
Adr
Ao
\g
\}
Ail
\ ’
Alar
\
Alb
\]
\
\
\
\
Alt
\
An
\
\
\
daee e
-
ooeooooee e
2056 Author
Flotte, T., 879 Hansen, C., 591 Isoherranen,N ., 1293 D-D 1690
Flynn, G., 848 Hanson, B., 1031 Ito, T., 720
Folestad, S., 494 Hanson, E., 31 Itoh. ¥Y SY
Fonseca, M., 423 Hara, K-i., 89 Iwakiri 910
Foraker, A., 110 Hard, R., 149
Forsberg, M., 848 Hashida, M 1401, 1452
Foster, N Hashimoto, T.. 368. 1846
I ountain, W., 16 Hashimoto, Y
I ranco, J 3] Hasunuma, M
I rederik, P., 653 Hawken, S$
I resta, M., 584 1101, 1323
I ricker, Hayashi,
I ried, M., 2001 Haynes, A.. 14
I riedman, M.. 1466 He, Z.. 720
Friis, J.. 1149 Heimbach, ' 1
I rijlink, H., 515, 143 Heimlich, K
I uji, M., 804 Herber, B.. 7
i ujichika, T., 93 Hermeling
I ujisawa, I Herron, J
I ujita, T., 897 Hickel, B
I umoto, S Hicks, W
I urness, M Hidaka, M.. 910
Higaki, K.. 6 Johns, R
Higgins, | Johnson \
Hilden, J Johnson N
abor, I Hilfinger Johnson W
a Hilgers Johnston J
anem-Quintanar, A.. | Hill. H Johnston K
sao, J 1626 Hincal, A Jones. D
ao. N.. 1600 Hinchcliffe Jones |
sardellil a J. Jr Hinrichs, W |J ONn SSOT ,
sedda L., 229 Hirano, K
selperina, S Hirayama
serman, ¢ Hirvonen. J
slacomini
Hisaka, A
slannavola Hivajvo, M
sibson, D Hoffman, A
sirault, H Holcombe. I
sittens, S Hollenbeck {
lass B Holme. K., 1015
10, M 169 Honevwell Neuven )
somez-Amores, | Hooton, J., 508
soodsaid, | 1373 Horie. K
Gordon, P., 1015 Horinouchi
Gorter, A., 1249
Goss, S., 1641 RFRRRRFRRRRRRSZFAAR RRRRRRFZRRRR RRRRARRRRRA Z AZAZAR
Gotoh, A
Goudonnet
Gralt, ¢ 122
Grattan, 1]
Greenblatt
Gref, R
Grienvenov
Csrieserat ARRFAARARR ARR
Grilfith 5 7
Grislau
Grove
Gu, ¢
Gauge)
Guy
Gwilt
oaoaeieeee e
H Hwang
Haberkorn, \ 1568
Hadgraft, J.. 1502
Haenel, E., 1961 Kennedy \
Haisma, H., 423 lacono, A., 252 Kennedy M
Hakala, K., 187 Ibalot, F., 2036 Kern, S 1574
Hallb66k, F., 373 Ida, Y., 1430 Keum Y S.. 13
Hamashin, C., 1258 Iguchi, K., 1309 Khan, M 1885S
Hamm, S., 409 Illum, L., 1474 Khil, J ) U >}
Hammarland-Udenaes, M., 618 Infante, M., 1697 Khio, 1 1309
Han, H-y., 1738 Inui, K-i., 1389 Khoo. S-M.. 1460
Han, Y-H., 597 Inuoue, N., 1932 Kikuchi M., 910
Hanes, J., 788 Ishizaki, J., 368, 1846 Kim, B-R 1351
Author Index
2058 Author Index
Ruiz, B., 797 Sivak, O.. 126 Ihakker,D ., 1192, 1200, 1210 Vromans, H., 169
Ruponen, M., 576 Six, K., 135, 1047 Thanos, C., 1093 Vuppugalla, R.. 81
Russell, $., 1258 Skellern, G., 1702 Thiele, L., 221
Ryu, S., 818 Slegers, ¢ 1977 Thiex, N., 1239 Ww
Sloan, K., 639 Thimon, M., 1047
Smaldone, G., 252 Thomas, H., 103 Wada. M.. 897
Smith, D., 1149, 1364 Thomas, S., 1713 Waddington, W
Smith, M., 1258 Thompson, K., 479 Waoener. C.. 448
Smith, R., 591, 1373 Thompson, M., 270 Walczak. R
Sabus, ( 1820
Smith, W., 1885 Thumshirn, M., 2001
Sadée, W., 3 Smolec, J., 1885 lijerina, M., 728 aalltlear.c e, I S
Sai, Y., 1119
Soares, T., | 3/3 rilquin, B., 1
aito, H., 1389
Séderberg, | lischler, M., 1820
ikaeda, T., 324 Soenawan, Tolle-Sander, S., 757
akai, T.. 552 Somsen, G., 1437 Tong, H., 1423
ikane, T., 1674
Song, H., 448 Toropainen, f
indefer, E., 460
Song, I-S., 597 Tothfalusi, |
iirnkdaerr,s , M.S.,. 1160030 Song, Y., 1612 Tovar, J.. 639
Sonveaux, I Townsend, I
irkari, M., 485
Soreghan, B., 17 Tozuka, Y
irsat. J-P.. 557 Spahn-Langguth, H Troutman, M
isaki, H Sparen, A., 494 Tsai. J-€ 63
ato, H Spindler, L., 1258 Tsuchiya
atoh. S
Squella, J Tsuji \
DPDPPiP vDoDl aiDneDn DDDY Stanworth Tsukimori
awadam Y
Stav. M.. 96 Tulkens, P.. 62
Scanlon, M
Steingoetter Tunblad, K., 618
Schaefer, |
Stella. \ 103 Tyagi, P.. 884
Schellekens, H.. 1903
Scherrmann, J-M., 904 1607 Stevens, H
Stinchcomb
Schink, A
Storm. G.. 64
Schmehl. T
Schmitt, W Stormer, White
SSSScccchhhhruuoileewztreez,,n, , JfJ . .R 1984 SSSSSttuuuorgggwoiiiehlyyvalaaal,mmmm ,aaa J J UUUUecccdhhhaiii,uyd maaim ,aH .,, I T1 513 WWWWhiiiideetedndrmeamay,a, n n.n A K T
Schurig, V., 1293 1394 Uguzzoli, M
Schwizer, W., 2001 Sunkara, G., 779, 1496 Uitto. O.. 646
Scott, D., 31 Surana, R., 1647 Ulbrich, K., 1558
Seeballuck I 1085 Suryanarayanan, R Ulmeanu, S., 131
Seeger, W., 2011 802. 1647. 1939 Ulmer, K., 63
Seo, M., 1302 Suzuki, H., 1163 { ludag, H
SSeeyzfaekrit,h , H., S., 16773 4 Suzuki, M., 701 { well, \ A-I5 7
Suzuki, R., 130 ]
Shaaya, O., 205 Swaan, P., 110 | sansky. H
Shackleford. D., 465 1460 Sweeney, T., 2028 | shigome
Shah, R., 81 Szot. G.. 1239 {
Shaik, M., 1485
Shanks, T 639 “
Sharma, V.. 1721
Shastri, \
Shawer, M
Shea, D., 275
Shedden K ick, J
Shelukar, S ihara. S
Shen, H., 1364 aipalensuu
Shen, J.. 135 ima, S
Shen, W-( ikahara, Y
Sherphof, G ikamura, N
Sheskin, T ikano, M
Sheu, H-M akano, S
Shi, H., 479 ikaura, Y
Shim, C-K., 24 ikehara
Shima. Y.. 368. 1846 ilvitic emul nl
Shin, H-C., 1381 imal enkataram
Shirakawa, T., 324 amufra erbeke
Shirasaka, D., 552 ing, A erreck
Shirasu, K., 611 ing. F., 16] ervoort
Shobe, E., 1149 ing-Liu, D AHLL@@€€€b0@€€CCLCC0ClH H b CCe s twepbdelr
Shu, C., 969 ini, T., 89 < eg, B.. 138]
Siahaan, T., 1523 avelin, S Vinardell, M
Sims, S., 1149 Telang, C., 660 Volberg, M
Singh, M., 247, 1485 Tendler, S., 508 von Briesen
Singh, S., 639 Terada, T 1389 von Moltke
Sinko, P., 390, 1015 Textor, M., 237 Vordés j.. 23 eowee e
Author Index
2059
ang, | ! Yoon. H
ang, T York, P
asuda, K 94 Yoshimura
isuhara 3 Yoshioka
iSUMOT
ites, (
i, H., 202
Y okogaw i
Yokoham
Pharmaceutical Research (. 2 December 2003 (© 2003)
Subject Index to Volume 20 (2003)
A Alum adjuvant, 969 Benzoic acid, 471 Brush-border membrane
: Alveolar epithelial cells, 1231 Best practices, 1885 38, 1133
Abbreviated New Drug Amino acid ester prodrugs, 13 BET monolayer, 308 B7 costimulatory
Application (ANDA)
Amino acid transporters, | Beta-blockers. 1496. 1946 Budesonide. 1690
ABCB1, 1141
Amino acids, 448 BH3 peptide, 889 Buffer systems, 1641
\ABC-B11, 537
aABtC t ranspoir tert, 359294, 4. 355w 3e7 AAmmoirnpohroeubsa,n E1N4®3,02 , |! 16: 7 BBiifcoanrabzoonlaet. e 1b1u7f fer system, 1641 BBuuffffeerrss,, h80i2g h-pH, 14132 7
caVae aileLanl IpO|p roteeiinnee mia,a. X 50 Amorphous lactose, 103>9 Bile acid sequestrants, 460 Burst, initial, . 71 49
A vatibsoornp . 8»/ ¥ 31.177. 900 Amorphous solid dispersion SIU Bile resa lts. 57 97. “ 900 ‘ Buspirone
C1e5c95s.p uon16,6 8 21: 766©,. 1199884 AAmmoorrpphhoouuss sstoaltied,s , 11443110 78 Biliary excretion, 31, 448, 910
Absorption, intestinal mp ‘les 5 Bi: nary mixtcurae s, 1939
i1p19e2e, e 1 200, pa1e21a0, e 1a6g74 e AAA\mmmnppphhhhyPiiidppprhhhiiiilodleliesic ,c prcoBo4d-6prwc ouyglecsyl,emo ednerxs2 t,0r 5i ns1,2 84 11‘ ’ BBBBiiiinnnnddddiiii;nn nnggge,, an8pf3oaf3in,rn siatpmye,e1c t0i0 f9i3 c60 p1r7o0t9e in Pe cSelltE i; fsihcio aml oge
Absorption, oral, 397, 1149, 16 Antiapoptotic cellular de eo
al 35 Binding sites, 53
bsorp 1. Dercutaneou Bioadhesion, 1093
. a 08, percmancous Antibody-directed enzyme
275, 1113 . Bioanalytic assay, 1885
prodrug therapy (ADEPT) o es
AAbbssoorrppttiioonn, rpatue,l mon1a4r09y , 545 An7 7t1 9i2 body-enzyme conjug Bioav1a84is.li agbhi1l4t7is4t .y , 1551.24 , 93116,2 6. 109136 68 ' suUbDcClI ONES, I >]
Absorption rate, duodenal: Anticancer drugs, 1558 546, 1954 1cO-2:Ht29GluH cocultur
Absorption rate limit, 848 Anticholinergics, soft Bioavailability, ocula | ilcein-AM
Absorption site, 1595 Bioavailability, oral | 7
Anticonvulsant activity
Absorptive quotient, 1210 Antiiieessttrrooggeen . 1063 Biochanin A. 1184
\bsorptive transport Antigen-presenting cells Biocompatibility
1210 Antimicrobial activity, 442 Bioconversion, xenobiot
Accumulation assay Antimicrobial agents, 114 Biodegradability, 884, 2011
Acetylsalicyclic acid Antimicrotubules, 45 Biodegradable polymers
Acrylic polymers, 1970 Antioxidant response Biodistribution, 96, 1239
Acryloyl-hydroxyethyl starch, 452 1351 Bioequivalence, 103
Activated endothelial cells, 64 Antipyrine. 187 Bioequivalence, scaled ave
Activation. 1001 Antisense oligonucleotic 3 382
Active transport, 1125
1565 Biologic activity
Acyclovir, 584
Antitubercular drugs, 176 Biologic matrices
Adaptive neural fuzzy inference ,
Gay e neu uzzy interenc Antitumor activity Biomarkers, 99¢
system, 143 Antiviral activit Biopharmaceutics
Additives, 283
Apolipoprotein B, 3 Biopharmacet
Adenosine kinase, 843
Apomorphine, 65 1730, 1738
Adenosine triphosphatas«
Apoptosis, 45, 351 ; 2 } Biopharmaceutics Classific
(ATPase), 158]
Aqueous form, |! System, 749 96
Adenosine triphosphate (ATP) Aaueous soluble coms a caaliaenias dhimelaiies ue
1201
LS! 12)
Adenovirus, 1A4 44 tke ‘ ii 64
ADEPT (antibody-directed g1u0e7o7u s solutions ) ’ 3isspphhoosspphhoonnaattee s
i 192 itter tast g2
Adeh1 nezsyimoen fporrco drugS US therapy), 423 Arginine > bas . , 25 1| 00 _. l-bOhriraoanli .t
Ad 24 Aasay. £5 05
adjuvants Arthroce
Adsorption Artificial neural networks 607
Aerosol, 2011 ASES (Aerosol Solvent Blood
A\erosol characterization 390
Aerosol 1 delivery +\(>O X AteEnxotlroal.c tio1n1 4] Svstem) s5l0o0odd ,
Li 714
Aerosol Solvent Extraction Atmospheric freeze > + ; 7
System (ASES) (ATMED) 1 Blood-placental bart
) proce , .
Aerosolizationg.e 25 14 Atomic force, "25 08 Blood-'r etinal barrier
Aerosols, 442, 20) > P : Blood sampling
¥ Atomic force micr« p B
\ggaa toxin Ss Sy 204 onnee tarti rgettiinngg
gglutinins, 833, 1258 . , = Bovine serum albumin
gation, 693, 1655, 17727 1 A\zziiddoo--33a''-- ddeeooxxyyttyhhm yymmiiddiinn' ee Bowman-Birk inhibitor
Ageiinngg, 177]1 2 3 m14o8n ophosphate pronuck | , 1K n)e -c17oo1nn2 j uga1| 77| 0 ]
Airway epeipitthhee lium 545. 779 Lettie 63"6 Braaine microvess-¢
Alacepril thiolesterase, 1309 monolavers. 3*
Albumin, 857 B Brain perfusior
Albumin, bovine serum, 81, 303 Brain transport
Albumin, human serum, 684 Baclofen esters Brain uptake ellu processing
Alcohols, 471 Bacteria, colonic, 42 Breast cancer 1, 1063 ellular upt ike >
Algorithms, 1401 Barbiturates, 864 Brefeldir 23] ntral nervous system
Alkylcarbonyloxymethy! Bcl-2 family proteins, 351 Brij, 1772 livery, 409
prodrugs, 639 RSY Bronchial epithelial cell lines bral cortex, 897
2060
Subject Index
2062 Subject Index
Emulsifiers, 1864 Flow-promoting agents, 804 Genotype, 552 Human, 545, 557. 646. 653. 684
Emulsifying wax, 1772 Flowability, 804 Geometric structure. 804 728. 957. 1389. 1466. 1595
Emulsion polymerization, 1786 Floxuridine, 1381 G418, 373 1612. 1690. 1721. 1804. 1932
Emulsions, water-in-oil, 130 Flufenamic acid, 1851 Glass transition, 143 55
Enantioselective analysis, 1881 Fluorescein, 714 Glass transition temperature, 308, Human colorectal cancer cel
Encapsulation, 442, 1873 Fluorescein hapten, 591 873, 1430, 1647 lines, 324
+19
Endo-lysosomal escape 21 Fluorescence, silver Glassy pharmaceuticals, 308 Human intestinal fluid, 900
Endocytosis, 212, 1812 ) nanoparticle-enhanced, 833 Ghioblastoma cells, 1804 Human nasal epithelium
Endothelial cell monolayers, 390 Fluorescence. x-ray. 435 Glioma, 738 Human skin cultures, 1113
Endothelial cells, blood-brain Fluorescence lifetime, 926 Giucocorticoids 194 Hydration, 257
barrier, 904 Fluorescence quenching, 1721 Glucose, 873 Hydration limit, 308
Endothelial cells, inflammed, 64 Fluorescence spectrum, 92 Glucuronides, 465 Hvdrogels. 303. 435. 884
Endothelin antagonists, 89 Fluorescent substrates, 53 Glutathione, reduced, 931, 1989 Hydrogels, thermosensitive, 1995
Enhancers, chemical, 264 Fluorinated esters, 918 Glycine, 283 Hydrolase, 1309
Enthalpy, 471 Fluorouracil, 639 Glycoprotein, 978 Hydrolysis, 1381
Enzyme activity, 1373 Flux, 639 p-Glycoprotein, 38, 45, 161, 545 Hydrolysis, E-ring, 1031
Enzyme inhibition, 1746 Folate conjugates, 714 597, 749, 757. 772, 900, 904 Hydrophilic drugs, 264
Enzyme inhibitors, 1989 Folate receptors, 417, 714 910, 1085, 1141, 1170, 1177 Hydrophilic macromolecules
Enzymosomes, 423 Folded sheets mesoporous 1184, 1200, 1210, 1225, 1595 Hydrophobic drugs
E100, 1533 material (FSM-16), 926 1607, 1794 Hydrostatic pressure
Epidermal growth factor, 818 Formulations, 969, 1302, 13:2 p-Glycoprotein inhibitor, 24 Hydrotropic agents
Epidermal growth factor Formulations, liquid, 195 ) p-Glycoprotein-mediated efflu Hydroxyethyl starch
liposomes, 229 Formulations, lyophilized, 1655 pump, 24 Hydroxymidazolam
Epidermal growth factor 1952 p-Glycoprotein substrate drugs Hydroxypropyi methylcellulos
receptors, 826, 833 Fraction dose absorbed, 1766 1163 (HPMC), 1047
Epidermal immunization, 969 Free bases, 270 Glycosylation, 319 Hydroxypropylmethylacrylamide
Epidermal retention, 270 Freeze-drying, 283, 485, 494, 802 Glycylsarcosine, 1389 (HPMA), 728
Epidermis, 1113, 1502 Frozen solutions, 660 Gradient, 257 Hydroxypropylmethylacryla
Epilepsy, 1293 Fruit juice, 169 Granulation, 1851 (HPMA) copolymer
Epithelial cells, 779, 788 FSM-16 (folded sheets Granulocyte colony stimulating conjugates, 360
Epithelium, airway, 545 mesoporous material), 926 factor 1i 9213] Hydroxyzine
Epithelium, intestinal, 397, 121 Fully human monoclonal Grapefruit, 169 Hyponatremia
Epithelium, nasal, 153, 11: antibody, 1952 Growth factor delivery, 1103 Hypothermia
Epithelium, renal, 319 Function, 765 Gustatory sensation, 1932 Hypoxanthine
Epitopes, 360, 591 Furnidipine
Epoetin, 1903 Fuzzy logic
Equations, 639
Equilibrium dialysis, 1015
Erythropoietin, 1903 G
Halofantrine, 1460
E-selectin, 64 Gabapentin, 897 Headspace analysis, 33
Esterification, 1381
Esterom® Solution, 1827 Gadolinium chelates, 2001 Heart, 58
Estradiol-17- 8-glucuronide Galactpoaseimdeansieg, 16 Heaeratr t did iseas e, 1908
1394 Galactosidase assay, 2 Heat, 1039
Ethylenediamine tetraacetic acid Gaali e S:V ii— ~1 145?2 HEK: 193 cece l
(E; DTA). 72 73 Gallici acidd, 1: 58 a HeLa 1733 2 7
Etoposide, 904 Gas chromatography } Hemolvsis. 11 169
Eudragit® E100, 135 Gas sparging, 164] Hen egg lysozyme, 59 mmunoOsup}
Eudragit RS. 1970 Gastric emptying, 1668 Heparin, low-molecular-weight In situ blood-br
Eutectic, | 939 Gastric-retention tablets )3 i rt
Ewing sarcoma, 1565 Gastrointestinal excretion, 91 atic delivery, 198 Situ Drain perfusion, 904
Excipients, 515 Gastrointestinal flow atic disposition
Excretion, 448 910 Gastrointestinal transit, | } la C 0)
Excretion, hepatobiliary, 89 Gastroretentive dosage f Hepatic metabolism, 1591, 1600
Exocytosis 12 1466 Hepatitis B surface antigen, 9¢
Expression, = 765" Gels,] 11666611] Hepatobiliary excrer tion, 89(
Gemini surfactants, | Hepatocytes, 89, 557, 1568 vitro characterizat
Expression level
I xsorptuion 910 Gene delivery, 738, 1103, 1444 Heterogenous compounds, 187 n vitro comparison, |
i xtendeledd releeia se 1452, 1730 High hydrost itic pressure 674 [ ro disintegration
Extrusion, 1047 Gene delivery, intestinal, 569 —20 26 itro drug transport
Gene delivery systems, 884 High-throughput, 13 3 f gene transfection
Gene delivery vehicles, 1995 1961 n vit 1 Vivo correlation
Gene expression, 324, 1373 Highly-variable drugs, 382
FaDu cells, 957 Gene expression, quantitative Higuichi law, 988 n vitro models, 788. 135
Fasting state, 1460 1373 Histidine, 1911, 195: 1 vitro P-gly ycoprotein functior
Fatty acids, 1612 Gene expression, transporter Hollow filler-binders, 515 765
Felodopine, 292 1119 HPLC (liquid high performance In vitro permeability, 1820
Fermentation, 429 Gene expression profiles, 843 chromatography), 693, 1881 In vitro permeation studies, | 409
Fetuin, 978 996 HPMA In vitro polarized transport, 1125
Fexofenadine, 1177 Gene therapy 3 8 879, 1444 (hyroxypropylmethylacrylamide), In vitro screening, 117
Fiber, membrane-coated 27 1779, 1995 722 5 In vitro screening model, 324
Fibrillation, 73 Gene therapy toxicity trials, 1779 HPMA In vitro simulation, 1926
Fictive temperature, 1430 Gene transfection, 738, 884 (hyroxypropylmethylacrylamide) In vitro tissue distribution, 857
Filler-binders, 515 Gene transfer, 345, 576 copolymer conjugates, 360 864
Flavonoids, 169, 1184 Genetic algorithm, 1401 HPMC (hydroxypropyl! In vitro transcellular transport
Flavors, 1932 Genomics, 1373 methylcellulose), 1047 1163
Subject Index
Japanese 55)
Je junal permeabi
ition. 460 jejunum=, 11
damage OHX4
n function
2064 Subject Index
Models remnant kidney, 1600 Non-small-cell lung cancer cell Paracellular route, 397 Phosphate ester, 848
Models 7-day. 96-well Caco lines, 1485 Paracellular transport, 110 Phosphatidylinositol, 126
1961 Noninvasive methods, 1508 Paracetamol, 1668 Phosphorylation 1838
Models solubility, 471 Nonsteroidal anti-inflammatory Parallel artificial membrane Phosphoryloxymethy! prodrugs
Models stochastic, 996 drugs, 205 permeability assay (PAMPA) 03]
Moisture 1039 Nonviral gene transfer, 1779 1820 *hotodynamic therapy 75 8
Moisture induced thermal activity Novel microemulsion enhancers Partial least squares, 1401 Photopolymer platform I y)
traces (MITAT), 308 264 Partially unfolded states, 17 Phthalimidomethylampicillin, 62 4
Molconn-Z software, 1401 Nrf2, | 35] Particle engineering, 485 Physical properties, 1952
Molecular dispersions, 1417 Nuclear envelope, 879 Particle interactions, 508 Physical stability 3 25
Molecular dynamics simulation, Nuclear localization sequences Particle size, 1417 Physicochemical properties
R73 28 Particle size distribution, 1702 96). 1274, 1474
Molecular mobility. 1655 Nuclear magnetic resonance Particles, composite, 1039 Physiologic dissolution media
Monitoring, 435, 494 (NMR), 465, 1274, 1634 Particles, reduced size, 1093 1641
Monoclonal antibodies, 826 Nuclear transport, 879
Partition coefficients, 275, 1502 Pigs, 1170
Monoclonal antibodies, fully Nucleation, 797 1858 Piroxicam, 1055
human, 1952 Nucleation model 1423
Partitioning, 1317, 1634 Pivampicillin, 624
Monte Carlo simulation YSS Nucleobase transport L804
Morphine, 618, 1474 Nucleoside transporters, 319 PEG. see Polyethylene glycol Plasma lipoproteins 1 ¢
Morphology, 1039 L804 Pellets. 1970 >| asma partit! ym coefficients
MRP (multidrug Nucleus 1574 Penetration, transdermal, 27 (Kpu) 857. 864
resistance-associated proteins) Nutrients 1119 Penetration enhancement Plasma surface ch
31.| 161. 324. 552 904. 1119 Peptide stability, 1746 Plasmids, 328
Peptide transporters, 1364 Plasticizers, 1647
1394. 158] 0
MMuulctuisd rugS hy resistance, 161 Oatp3 (polypeptide subtype 3) Peptides, targeted proapoptotic PLI( p} olvilP EG lysin' e ) sra1fitLee¢d
Multidrug resistance-associated 720 RRY polv(ethvlene glycol)
proteins (MRP), 31 161. 324 Occludin, 1838 Percutaneous absorption Pluronic blaocecllk copol,y mer
552. 904. 1119. 1394 LSS] Octanol-water distribution 77) 975 17 LORS
Multidrug resistance protein coetficient 72 Percutaneous permeation Pluronic P85, 1581
substrate drugs, 1163 OCTN2 (organic cation Perflubron, 16, 918 Pols I if sinine. 153
Multidrug resistant human ur insporter ) 11112323 Perfluorocarbon emulsion Polv(acrviovl-hyvdroxvet
ovarian cancer cells, 351 Ocular absorption, 1409 Perfusion, hepatic, 81, 198 starch), 452
Multiple antigenic peptide Ocular bioavailability, 584 Perfusion, intestinal, 1163 Poly(alpha-hydroxy acids
Mus1c6a8r] inic receptor subtypes OOccuullaarr dirrruigt atidoenl,i very1.6 97 96 Per3m9e abi4l4i8t y 705 749 Poly$4a3m idoamine dendrin
Mutagenesis Site directed, 19 Oil-loaded nanoparticles 1149. 135 1820 Pioy]l y(buytt yicv‘ anoacryr\
Oleate. 1267 Permeability paracellular os
Oligonucleotides, antisense Permeability Passive >] Polycarbophil, thiolated
Oligopeptide transporter Permeability issays, 196] P oly(cyanoacryiate ), 0/74
Oncogenes,. 1565 Permeability enhancemen Pooll y(epsilon-caprolactoonme
inocapsules, 1063, 1071 Opsonization, 1063 Permeabilization, 879 )P olvest‘ er-polv" (ethvnleste ne
inoemulsion, 738, 1274 Oral ibsorption, 397 Permeation, 772, 1409, 167 nanoparticies, LUOS
inofibers, drug-laden, 810 196] Permeation, percutaneous branched
inopartic 409, 4 79 Oral idministration Permeation enhancer 0
674. 705 Oral antigen delivery Permeation rates, 275
L864 Oral Moavailability Personalized chemotherapy
inoparticles Oral drug absorption Pep substrates, 390
intiestrogen-loaded, 1063 Oral drug delivery, 931 pH
inoparticles, oil-loaded, 1274 Oral drug delivery system LYsSy pH, of buffers
inoparticles Oral ingestion, 200] pH dependency
polyester-polysaccharide Oral phosphate prodrugs, 848 pH-triggered
N inoparticles, solid lipid, 127 Oral tolerance, 130 Ph 1GOCVLOSIS
N anospheres, 117, 584, 1565 Oral vaccines, 1258 Pharmaceutica | solids]
Naproxen, 187 Organic inions Pharmaceuticals 3?
Nasal administration Organic cation-t Pharmacodynamic
Nasal epithelium, 15 complexes, 59 Pharmacodynami
1838 Organic cation transporters Phar Cogs
ebulization 44? 2011 Organic solvents, 47 Pharmacokinetic
eural retina 1364 Ovalbumin, 130
euronal cultures, 897 Ov irian cancer, 351 Pharmacokinet
europathic pain, 1752 Ovarian carcinoma cells, 728 552. 684. 857
eurotoxicity, 937 Overexpression, 1581 Pharmacokinetic Oss ~ ()
eutral lipid-binding sites 1009 Oxazolidinones Pharmacokinetics Poly(D.L-lactide-co rivcolide )
Nicotine, 1474 Oxidation 684 hills
Nicotinic acid esters, 918 Oxidative dam Pharmacology. cutaneous Poly( D.I lactide-co-glycolide )
Nifedipine, 292 Oxybutinin, | Pharmacology. v itreoretina m rosph res. 2 37 SS4
Nimesulide Pharynx, 957 DI
Poly lactide co givcolide }
Nimodipine Phase diagrams nanoparticies
N-in-one cocktails, | Phase separation, 135, 1047 Poly(lactone ), 668
Nisoldipine, 292 Paclitaxel Phase transformation, 797 Polyil lysine )-grafted
Nitrendipine, 292 1302, 1864 Phase transitions, 283, 802 poly(ethylene glycol)
Nitric oxide synthase, 897 Palmitoyl poly-l i1 Vsi Phenethyl isothiocyanates conjugates, 2a5r n
NMR (nuclear magnetic Paracellular pathway 1984 Phenobarbital, 557 Polymer drug carriers, 1558
resonance ), 465, 1634, 2174 Paracellular permeability, 15 Phenothiazines Polymer molecular weight 1039
Non-occlusive pretreatment, 65 4 1838 Phenylalanine, |! Polymer surface degradation 149